• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-3/A filed by Akari Therapeutics plc

    7/8/26 4:15:27 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKTX alert in real time by email
    S-3/A 1 forms-3a.htm S-3/A

     

    As filed with the Securities and Exchange Commission on July 8, 2026

     

    Registration No. 333-297257

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    Amendment No. 1

    To

    FORM S-3

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    AKARI THERAPEUTICS, PLC

    (Exact name of registrant as specified in its charter)

     

    England and Wales   2834   98-1034922

    (State or other jurisdiction of

    incorporation or organization)

      (Primary Standard Industrial
    Classification Code)
     

    (I.R.S. Employer

    Identification No.)

     

    401 East Jackson Street, Suite 3300

    Tampa, FL 33602

    (929) 274-7510

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Abizer Gaslightwala

    President and Chief Executive Officer

    401 East Jackson Street, Suite 3300

    Tampa, FL 33602

    (929) 274-7510

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Gary Emmanuel, Esq.

    Win Rutherfurd, Esq.

    Greenberg Traurig, LLP

    One Vanderbilt Avenue

    New York, NY 10017

    Tel: (212) 801-9200

     

     

     

    Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this Registration Statement.

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller Reporting Company ☒
        Emerging Growth Company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

    The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

     

     

     

     
     

     

    EXPLANATORY NOTE

     

    This Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-297257) is being filed solely for the purpose of filing certain exhibits. Accordingly, this Amendment No. 1 consists only of the facing page, this explanatory note, Item 16 of Part II of the Registration Statement, the signature page to the Registration Statement, and the filed exhibits. The remainder of the Registration Statement is unchanged and has therefore been omitted.

     

     
     

     

    PART II

     

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 16. Exhibits

     

    The following exhibits are attached hereto:

     

    Exhibit No.   Description
    3.1   Amended Articles of Association of Akari Therapeutics, Plc (incorporated by reference to the Exhibit 3.1 to Registrant’s Current Report on Form 6-K, as filed with the SEC on July 8, 2023).
    4.1   Form of Deposit Agreement among the Registrant, Deutsche Bank Trust Company Americas, as Depositary, and all Owners and Holders from time to time of American Depositary Shares issued thereunder (incorporated by reference to the exhibit 99.(A) previously filed with the Registrant’s Registration Statement on Form F-6 (No. 333-185197) filed on November 30, 2012).
    4.2   Amendment to Deposit Agreement among the Registrant, Deutsche Bank Trust Company Americas, as Depositary, and all Owners and Holders from time to time of American Depositary Shares issued thereunder (incorporated by reference to the registrant’s Post-Effective Amendment No. 1 to Registration Statement on Form F-6 (No. 333-185197) filed on December 24, 2013).
    4.3   Form of American Depositary Receipt; the Form is Exhibit A of Amendment No. 1 to the Deposit Agreement (incorporated by reference to the exhibit previously filed with the Registrant’s Registration Statement on Form F-6 (No. 333-185197) filed on November 30, 2012).
    4.4   Form of Amendment No. 2 to Deposit Agreement (incorporated by reference to the exhibit previously filed with the Registrant’s Post-Effective Amendment on Registration Statement Form F-6 (File No. 333-185197) filed on September 9, 2015).
    4.5   Form of Amendment No. 3 to Deposit Agreement (incorporated by reference to the exhibit previously filed with the Registrant’s Post-Effective Amendment on Registration Statement Form F-6 (File No. 333-185197) filed on August 17, 2023).
    4.5   Form of Amendment No. 4 to Deposit Agreement (incorporated by reference to the exhibit previously filed with the Registrant’s Post-Effective Amendment on Registration Statement Form F-6 (File No. 333-185197) filed on March 31, 2026).
    4.6   Form of American Depositary Receipt; the Form is Exhibit A of Amendment No. 2 to the Deposit Agreement (incorporated by reference to the exhibit previously filed with the Registrant’s Post-Effective Amendment on Registration Statement Form F-6 (File No. 333-185197) filed on September 9, 2015).
    4.7**   Form of Pre-Funded Warrant issued by Akari Therapeutics, Plc in connection with the May Private Placement.
    4.8*   Form of Series H Warrant issued by Akari Therapeutics, Plc in connection with the May Private Placement.
    4.9*   Form of Series I Warrant issued by Akari Therapeutics, Plc in connection with the May Private Placement.
    4.10**   Form of Series J Warrant issued by Akari Therapeutics, Plc in connection with the May Private Placement.
    5.1*   Opinion of Greenberg Traurig LLP as to the legality of the securities being registered.
    10.1**   Form of Securities Purchase Agreement dated as of May 20, 2026 between Akari Therapeutics, Plc and the purchasers party thereto (incorporated by reference to Exhibit 10.1 previously filed with the Registrant’s Current Report on Form 8-K as filed with the SEC on May 22, 2026).
    10.2**   Amendment No.1 to the Securities Purchase Agreement dated as of June 23, 2026 between Akari Therapeutics, Plc and the purchasers party thereto (incorporated by reference to Exhibit 10.1 previously filed with the Registrant’s Current Report on Form 8-K as filed with the SEC on June 26, 2026).
    23.1*   Consent of BDO USA, P.C.
    23.3*   Consent of Greenberg Traurig LLP (included in Exhibit 5.1)
    24.1**   Power of Attorney (included in signature page)
    107**   Filing Fee Table

     

    * Filed herewith.

    ** Previously Filed.

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Tampa, Florida on this July 8, 2026.

     

    AKARI THERAPEUTICS, PLC  
         
    By: /s/ Abizer Gaslightwala  
    Name: Abizer Gaslightwala  
    Title: President and Chief Executive Officer  
      (Principal Executive Officer)  

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

     

    Name   Title   Date
             
    *   President, Chief Executive Officer and Director   July 8, 2026
    Abizer Gaslightwala   (principal executive officer)    
             
    *   Interim Chief Financial Officer   July 8, 2026
    Kameel Farag   (principal financial and accounting officer)    
             
    *   Chairman   July 8, 2026
    Hoyoung Huh, M.D., Ph.D.        
             
    *   Director   July 8, 2026
    Ray Prudo, M.D.        
             
    *   Director   July 8, 2026
    Samir R. Patel, M.D.        
             
    *   Director   July 8, 2026
    Sandip I. Patel        
             
    *   Director   July 8, 2026
    Robert Bazemore        
             
    * By: /s/ Abizer Gaslightwala        
    Abizer Gaslightwala        
    Attorney-in-fact        

     

     

    Get the next $AKTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKTX

    DatePrice TargetRatingAnalyst
    7/20/2026$30.00Hold → Buy
    Maxim Group
    4/8/2026Buy → Hold
    Maxim Group
    1/5/2026$1.00Buy
    Ladenburg Thalmann
    7/18/2025$5.00Buy
    Maxim Group
    More analyst ratings

    $AKTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Akari Therapeutics upgraded by Maxim Group with a new price target

    Maxim Group upgraded Akari Therapeutics from Hold to Buy and set a new price target of $30.00

    7/20/26 8:23:24 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics downgraded by Maxim Group

    Maxim Group downgraded Akari Therapeutics from Buy to Hold

    4/8/26 8:06:49 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ladenburg Thalmann initiated coverage on Akari Therapeutics with a new price target

    Ladenburg Thalmann initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $1.00

    1/5/26 8:57:02 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics

    TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced a strategic research collaboration with Whitehawk Therapeutics, a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved ADC cancer treatments. Under the collaboration, the companies will conduct a series of focused preclinical studies evaluating Akari's proprietary PH1 spliceosome-modulating payload technology in combination with Whitehawk’s topoisomerase I inhibitor (TOP1i) ADC

    7/21/26 7:05:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board

    Globally recognized leader in early-phase oncology clinical development and experimental therapeutics Strengthens strategic expertise as Akari advances its novel ADC payload that modulates RNA splicing into future Phase 1 First-in-Human trial TAMPA, Fla. and LONDON, July 07, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the appointment of Patricia LoRusso, D.O. to its Scientific Advisory Board. "Dr. LoRusso is one of the most influential leaders in oncology drug development, and her appointment represents a significant addition to Aka

    7/7/26 8:55:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones

    TAMPA, Fla. and LONDON, June 29, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the completion of its previously announced PIPE through the consolidation of the remaining scheduled investment closings into a single funding event. Combined with warrant exercises completed in May, the Company received approximately $8.3 million in total capital during Q2 2026. "We appreciate the decision of our investor group to complete the remaining funding earlier than originally scheduled, and for some of these investors to further increase their commi

    6/29/26 8:45:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Gaslightwala Abizer bought $19,540 worth of American Depositary Shares representing Ordinary Shares (21,000 units at $0.93), increasing direct ownership by 8% to 298,574 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    8/29/25 4:55:12 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Gaslightwala Abizer bought $7,120 worth of American Depositary Shares representing Ordinary Shares (6,146 units at $1.16), increasing direct ownership by 2% to 277,574 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/25/25 4:30:04 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Gaslightwala Abizer bought $12,000 worth of American Depositary Shares representing Ordinary Shares (10,000 units at $1.20), increasing direct ownership by 4% to 271,428 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/24/25 4:30:10 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Patel Samir Rashmikant exercised 22,474 units of American Depositary Shares representing Ordinary Shares at a strike of $0.43 (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    7/17/26 6:03:07 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Interim CFO Farag Kameel D. was granted 18,830 units of American Depositary Shares representing Ordinary Shares, increasing direct ownership by 1,161% to 20,452 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/25/26 8:06:51 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO Gaslightwala Abizer

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/25/26 8:04:19 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    SEC Filings

    View All

    SEC Form EFFECT filed by Akari Therapeutics plc

    EFFECT - Akari Therapeutics Plc (0001541157) (Filer)

    7/14/26 12:15:21 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form S-3/A filed by Akari Therapeutics plc

    S-3/A - Akari Therapeutics Plc (0001541157) (Filer)

    7/10/26 4:15:47 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form S-3/A filed by Akari Therapeutics plc

    S-3/A - Akari Therapeutics Plc (0001541157) (Filer)

    7/8/26 4:15:27 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Leadership Updates

    Live Leadership Updates

    View All

    Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board

    Globally recognized leader in early-phase oncology clinical development and experimental therapeutics Strengthens strategic expertise as Akari advances its novel ADC payload that modulates RNA splicing into future Phase 1 First-in-Human trial TAMPA, Fla. and LONDON, July 07, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the appointment of Patricia LoRusso, D.O. to its Scientific Advisory Board. "Dr. LoRusso is one of the most influential leaders in oncology drug development, and her appointment represents a significant addition to Aka

    7/7/26 8:55:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

    TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Prafulla Gokhale, Ph.D., Director of the Experimental Therapeutics Core and the Lurie Family Imaging Center at Dana-Farber Cancer Institute, to its Scientific Advisory Board. "Dr. Gokhale's expertise in experimental therapeutics, RNA biology and translational oncology comes at a pivotal time as we advance AKTX-101 toward the clinic," commented Abizer Gaslightwala, President and CEO of Akari Therapeutics. "His proven track record to develop novel t

    2/26/26 9:10:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board

    TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Olga Anczukow, Ph.D. to its Scientific Advisory Board (SAB). Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics commented, "Dr. Anczukow is a leading authority in RNA splicing and cancer biology, an area of growing importance for the development of next-generation therapeutics. Her scientific rigor, translational mindset, and experience advancing RNA-focused discoveries toward clinical relevance make her an outstandin

    2/23/26 8:50:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Financials

    Live finance-specific insights

    View All

    Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

    BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. At a General Meeting held in relation to the merger at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London, shareholders approved the Company's issuance of shares in connection with the proposed merger, with approximately 99% of shares present at the General Meeting, in person or by proxy, voted in support. "I am thrilled to announce this

    11/8/24 8:00:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger

    BOSTON and LONDON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the effectiveness of the Form S-4, originally filed with the SEC on September 13, 2024 related to the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. The Form S-4 was declared effective by the SEC on October 11, 2024 allowing the Company to definitively schedule the General Meeting to be held in relation to the merger. The General Meeting will be held at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London. "I am so excited to be

    10/15/24 8:00:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders

    Interim CEO employment contract consists solely of equity compensationSamir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, in follow up to the May 1st announcement that Samir R. Patel, M.D., has assumed the role of Interim President & CEO, provides detail of Dr. Patel's employment compensation. Dr Patel's employment contract reaffirms his desire to align his success directly with the success of the company's shareholders. Dr. Patel will be compen

    6/5/24 8:00:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    12/6/24 4:00:28 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    6/20/24 7:30:07 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Akari Therapeutics plc

    SC 13D - Akari Therapeutics Plc (0001541157) (Subject)

    6/18/24 4:15:30 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care